

# Top 10 Most Promising Drugs in 2018

Rank	Drug	Company	Indication	Projected revenue (in US\$)	Projected Year
#1	 <b>DUPIXENT</b> <sup>®</sup> (dupilumab) Injection 300mg	Sanofi and Regeneron	Dermatology	4 billion	2022
#2	 <b>OCREVUS</b> <sup>™</sup> ocrelizumab	Roche/Genentech	Immunology, Musculoskeletal	4 billion	2022
#3	 <b>IMFINZI</b> <sup>™</sup> durvalumab Injection for Intravenous Use 50 mg/mL	AstraZeneca	Oncology, Urology	4 billion	2023
#4	 <b>OZEMPIC</b> <sup>®</sup> semaglutide injection	Novo Nordisk	Endocrinology, Family Medicine	3.170 billion	2023
#5	 <b>Zejula</b> <sup>™</sup> niraparib capsules 100 mg	Tesaro	Oncology, Obstetrics/ Gynecology (Women's Health)	1.642 billion	2022
#6	 <b>HEMLIBRA</b> <sup>®</sup> emicizumab-kxwh Injection for subcutaneous use	Roche/Genentech	Hematology	1.6 billion	2022
#7	 <b>Tremfya</b> <sup>®</sup> (guselkumab)	Janssen Biotech	Dermatology, Immunology	1.6 billion	2022
#8	 <b>KISQALI</b> <sup>®</sup> ribociclib 200 mg tablets	Novartis	Oncology, Obstetrics/ Gynecology (Women's Health)	1.5 billion	2022
#9	 <b>nerlynx</b> <sup>™</sup> (neratinib) tablets	Puma Biotech	Oncology	1.363 billion	2022
#10	 <b>Verzenio</b> <sup>™</sup> abemaciclib	Eli Lilly	Oncology, Obstetrics/ Gynecology (Women's Health)	1.3 billion	2021

Source: "Top 31 Most Promising Drugs 2018." Reporting by Luca Dezzani (MD). Published on February 14, 2018.